Author： Roblin Xavier Dronne William Paul Stéphane Tedesco Emilie Del
Publisher： Future Science
ISSN： 2041-6792
Source： Clinical Investigation, Vol.3, Iss.5, 2013-05, pp. : 479-492
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Anti-TNF therapy is the most important treatment for inflammatory bowel disease patients. However, primary nonresponders are frequent and clinical recurrence under maintenance therapy is reported in 40% of the treated patients. The aim of this article is to explain the most important targets for the future of treatments in inflammatory bowel disease and to report the results of these news drugs in clinical practice. Two Phase III studies clearly indicate the interest of golimumab and vedolizumab in induction and maintenance treatment for ulcerative colitis patients. Soon it will be possible to analyze the principal regulation defect in each patient to design a more personalized treatment. Before this step, it is important first to try to optimize treatment and then to consider a switch to another drug.
Related content
Letter: diverticulosis in inflammatory bowel diseases
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 39, Iss. 8, 2014-04 ,pp. :
Access to resources
Recommend
